Share on StockTwits

Shares of Fresenius Medical Care AG & Co. (NYSE:FMS) have received a consensus rating of “Hold” from the twelve ratings firms that are covering the company, AnalystRatingsNetwork reports. Three research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $36.10.

A number of research firms have recently commented on FMS. Analysts at Credit Suisse upgraded shares of Fresenius Medical Care AG & Co. from a “neutral” rating to an “outperform” rating in a research note on Thursday. Separately, analysts at Piper Jaffray cut their price target on shares of Fresenius Medical Care AG & Co. from $34.00 to $33.00 in a research note on Monday, May 12th. Finally, analysts at Zacks downgraded shares of Fresenius Medical Care AG & Co. from a “neutral” rating to an “underperform” rating in a research note on Wednesday, April 23rd. They now have a $32.40 price target on the stock.

Fresenius Medical Care AG & Co. (NYSE:FMS) traded up 2.79% on Thursday, hitting $33.19. 48,821 shares of the company’s stock traded hands. Fresenius Medical Care AG & Co. has a 52-week low of $30.75 and a 52-week high of $37.01. The stock’s 50-day moving average is $32.60 and its 200-day moving average is $34.28. The company has a market cap of $20.018 billion and a P/E ratio of 17.93.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its earnings data on Wednesday, May 7th. The company reported $0.34 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.38 by $0.04. Analysts expect that Fresenius Medical Care AG & Co. will post $1.70 EPS for the current fiscal year.

Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.